Changes in UCB’s Executive Committee | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Changes in UCB’s Executive Committee

  • Michele Antonelli, Head of UCB's Technical Operations and Quality team joins UCB's European Commercial Operations team as Executive Vice President & Managing Director of UCB France
  • Mark McDade, UCB’s Chief Operating Officer, takes responsibility for UCB's Technical Operations
  • Quality Assurance and Drug Safety report directly to Roch Doliveux, UCB's CEO

BRUSSELS, December 28, 6.30 pm (CET) - regulated information - UCB today announced changes within the company’s Executive Committee as of January 1, 2012. Michele Antonelli, currently Head of UCB's Technical Operations and Quality team, will join the European Commercial Operations team as Executive Vice President & Managing Director of UCB France.

After building significant expertise in manufacturing, supply chain and quality in Biopharma, Michele Antonelli has chosen to expand his skills and competencies in European Commercial Operations.

"Michele’s move is fully in line with UCB’s culture to provide opportunities for people to develop and express their talent,” says Fabrice Enderlin, Executive VP Human Resources and Communication, UCB. “For more than three years under Michele’s leadership, the Technical Operations and Quality team has gone through an outstanding transformation, leading to a streamlined high-performing pharmaceutical and biotechnology network within UCB. Michele will for sure bring a lot of value to UCB’s French operations and ensure continued strong leadership of the team,” he added.

Michele Antonelli will also be appointed Chairman of the UCB Farchim Board in Switzerland, where he will continue overseeing and supporting the construction of the new Bioplant in Bulle. While taking on his new role in France, Michele Antonelli will no longer sit on UCB’s Executive Committee.

Michele Antonelli’s Technical Operations mandates will be taken over by Mark McDade, Executive VP and Chief Operating Officer, UCB. The Quality Assurance and Drug Safety team will report to Roch Doliveux, Chief Executive Officer, UCB.

UCB's Executive Committee is comprised of the following members as of January 1, 2012:

Roch Doliveux
, Chief Executive Officer and Chairman of the Executive Committee
Greg Duncan
, Executive Vice President and President of North American Operations
Fabrice Enderlin
, Executive Vice President Corporate Human Resources and Communication
Ismail Kola
, Executive Vice President and President UCB NewMedicines™
Iris Loew-Friedrich
, Executive Vice-President Global Projects and Development and Chief Medical Officer
Mark McDade
, Executive Vice President and Chief Operating Officer
Jean-Christophe Tellier
, Executive Vice President and President of European Operations
Detlef Thielgen
, Executive Vice President and Chief Financial Officer
Bob Trainor
, Executive Vice President and General Counsel

For further information:
Antje Witte, Investor Relations UCB
T +32.2.559.9414,
France Nivelle, Global Communications, UCB
T +32.2.559.9178,

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Asset Download

Stay up-to-date on the latest news and information from UCB